Aptevo Therapeutics (NASDAQ: APVO) outlines bispecific cancer pipeline and AML data

NodeGuardian · 2026-04-10T19:45:08+00:00

Aptevo Therapeutics provided an update on its bispecific cancer pipeline, highlighting mipletamig's strong clinical results in AML with an 86% benefit rate and no severe side effects. The company is also progressing with ALG.APV-527 and several preclinical candidates.

NodeGuardian

2026-04-10 19:45:08

Abstract generation in progress

Aptevo Therapeutics (NASDAQ: APVO) detailed its bispecific cancer pipeline and clinical trial data for its lead acute myelogenous leukemia (AML) candidate, mipletamig, in its latest 10-K filing. Mipletamig, a CD123xCD3 T-cell engager, demonstrated an 86% clinical benefit rate and no cytokine release syndrome in frontline AML patients during the RAINIER trial. The company is also advancing ALG.APV-527 for solid tumors, as well as six preclinical candidates leveraging its ADAPTIR and ADAPTIR-FLEX platforms.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes